YOU ARE HERE:
New drugs news
page  of 14
 
Headline
Date
  Brazil rejects tenofovir patent
05.09.08
  Etravirine (Intelence) approved in Europe for treatment-experienced patients
02.09.08
  Raltegravir may cause temporary worsening of pre-existing depression
02.09.08
  Next generation first-line NNRTI, rilpivirine (TMC278) potent; lowest dose better-tolerated than efavirenz at 96 weeks
19.08.08
  Heat-stable ritonavir tablet equivalent to soft gel capsule; may be approved next year
15.08.08
  Two new NNRTIs look promising in early clinical trials
08.08.08
  Two novel immune therapies in early investigation: autologous dendritic cells and CD4 zeta gene-modified T cells
07.08.08
  Slowing CD4 cell decline with IL-2 allows HIV treatment to be deferred by 92 weeks
06.08.08
  Raltegravir versus efavirenz in treatment-naïves at 96 weeks: continued efficacy and fewer adverse effects
06.08.08
  Gilead now testing ritonavir replacement in human studies
23.07.08
  Roche to halt HIV drug research
14.07.08
  Atazanavir approved for first-line treatment in Europe
24.06.08
  Nearly all patients with NNRTI resistance could benefit from etravirine, UK analysis shows
09.05.08
  New way of attacking HIV looks promising in early trial
25.03.08
  Merck licenses fusion inhibitor to International Partnership for Microbicides
12.03.08
  Studies begin to define who will do best on bevirimat
06.03.08
  CROI: Choice of nucleoside analogue in co-infection: tenofovir associated with better response to HCV therapy
15.02.08
  Boehringer-Ingelheim begins trial of once-daily extended release nevirapine
13.02.08
  FDA approves generic atazanavir
13.02.08
  CROI: Once daily Kaletra tablets non-inferior to twice daily dose
08.02.08

page  of 14